Lexicon Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LEXICON PHARMS INC, and what generic alternatives to LEXICON PHARMS INC drugs are available?
LEXICON PHARMS INC has one approved drug.
There are three US patents protecting LEXICON PHARMS INC drugs.
There are seventy patent family members on LEXICON PHARMS INC drugs in thirty-two countries and twelve supplementary protection certificates in eleven countries.
Summary for Lexicon Pharms Inc
International Patents: | 70 |
US Patents: | 3 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Drugs and US Patents for Lexicon Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-002 | May 26, 2023 | RX | Yes | Yes | 8,476,413 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-001 | May 26, 2023 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-002 | May 26, 2023 | RX | Yes | Yes | 7,781,577 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-002 | May 26, 2023 | RX | Yes | Yes | 8,217,156 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-001 | May 26, 2023 | RX | Yes | No | 7,781,577 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-001 | May 26, 2023 | RX | Yes | No | 8,217,156 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Lexicon Pharms Inc | INPEFA | sotagliflozin | TABLET;ORAL | 216203-002 | May 26, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Lexicon Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Norway | 20091700 | ⤷ Try a Trial |
Denmark | 2308841 | ⤷ Try a Trial |
Russian Federation | 2011105797 | ⤷ Try a Trial |
Ukraine | 98123 | ⤷ Try a Trial |
Taiwan | 201006808 | ⤷ Try a Trial |
Japan | 5889453 | ⤷ Try a Trial |
Brazil | PI0717156 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Lexicon Pharms Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2089361 | 42/2019 | Austria | ⤷ Try a Trial | PRODUCT NAME: SOTAGLIFLOZIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1363 (MITTEILUNG) 20190430 |
2089361 | 2019C/538 | Belgium | ⤷ Try a Trial | PRODUCT NAME: SOTAGLIFLOZINE OF EEN AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1363 20190430 |
2089361 | C201930054 | Spain | ⤷ Try a Trial | PRODUCT NAME: SOTAGLIFLOZINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/19/1363; DATE OF AUTHORISATION: 20190426; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1363; DATE OF FIRST AUTHORISATION IN EEA: 20190426 |
2089361 | 132019000000113 | Italy | ⤷ Try a Trial | PRODUCT NAME: SOTAGLIFLOZIN O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(ZYNQUISTA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1363, 20190430 |
2089361 | SPC/GB19/054 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/19/1363 (NI) 20190430; UK PLGB 53567/0001 20190430 |
2089361 | 1990043-0 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SOTAGLIFLOZIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/19/1363 20190430 |
2089361 | CA 2019 00042 | Denmark | ⤷ Try a Trial | PRODUCT NAME: SOTAGLIFLOZIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1363 20190430 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.